p53 kills cells by target gene activation and transcription-independent action. However, a mechanism for the latter was unknown. In the previous grant period we discovered that a fraction of induced p53 rapidly trans-locates to the mitochondrial surface of cultured cells during p53-dependent death. Importantly, bypassing the nucleus by targeting p53 to mitochondria is sufficient to launch apoptosis, p53 translocation also occurs in vivo in irradiated thymocytes. We explored the apoptogenic mechanism of mitochondrial p53 and showed that the p53 protein itself directly induces permeabilization of the outer mitochondrial membrane by forming complexes with the protective BcIXL and Bcl2 proteins, resulting in rapid cytochrome C release. We modeled and mapped the interaction: p53 binds to BcIXL via its DNA binding domain. We probed the significance of mitochondrial p53 and showed that breast cancer-derived, transactivation-deficient missense mutants of p53 concomitantly loose the ability to interact with BcIXL. This opens the possibility that p53 mutations represent 'double-hits' by simultaneously abrogating the transcriptional and mitochondrial apoptotic activity of p53. We propose a pathway where p53 exerts a rapid and direct apoptogenic role at the mitochondria, thereby jump-starting and amplifying the transcription-based apoptotic action of p53. This proposal is now exploring the in vivo action of mitochondrial p53 by focusing on genetic experiments.
Aim I further defines function and regulation of this pathway.
Aim II uses retroviral gene transfer of mitochondrially-targeted wtp53 in the mouse Elx-myc lymphoma model to test for tumor killing apoptotic potential of pre-existing tumors.
Aim llI generates a transgenic model to test mitochondrially-targeted wtp53 for tumor suppressive action during spontaneous tumorigenesis. If confirmed, the mitochondrial p53 pathway will open the door towards therapeutic exploitation since it could add an important synergistic modality to the p53-based arsenal of cancer therapeutics that are currently developed. ? ?
|Yallowitz, A R; Alexandrova, E M; Talos, F et al. (2014) p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis. Cell Death Differ 21:645-54|
|Hanel, W; Marchenko, N; Xu, S et al. (2013) Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ 20:898-909|
|Hanel, Walter; Moll, Ute M (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113:433-9|
|Vaseva, Angelina V; Marchenko, Natalie D; Ji, Kyungmin et al. (2012) p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149:1536-48|
|Li, D; Marchenko, N D; Moll, U M (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18:1904-13|
|Hagn, Franz; Klein, Christian; Demmer, Oliver et al. (2010) BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem 285:3439-50|
|Marchenko, N D; Hanel, W; Li, D et al. (2010) Stress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-alpha3 binding. Cell Death Differ 17:255-67|
|Vaseva, Angelina V; Moll, Ute M (2009) The mitochondrial p53 pathway. Biochim Biophys Acta 1787:414-20|
|Vaseva, Angelina V; Marchenko, Natalia D; Moll, Ute M (2009) The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle 8:1711-9|
|Wolff, Sonja; Erster, Susan; Palacios, Gustavo et al. (2008) p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res 18:733-44|
Showing the most recent 10 out of 16 publications